Atsushi Ogata Selected Research

tocilizumab (atlizumab)

9/2019	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
3/2019	IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
1/2019	Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
1/2018	A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
6/2017	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
10/2015	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
5/2015	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
3/2015	Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.
1/2015	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
3/2014	Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsushi Ogata Research Topics

Disease

26	Rheumatoid Arthritis 01/2021 - 06/2003
9	Arthritis (Polyarthritis) 06/2015 - 05/2003
5	Multiple Myeloma 12/2007 - 01/2002
4	Hemorrhage 11/2020 - 01/2017
4	Systemic Scleroderma (Systemic Sclerosis) 01/2015 - 06/2003
4	Autoimmune Diseases (Autoimmune Disease) 02/2014 - 01/2004
3	Psoriatic Arthritis 01/2021 - 01/2012
3	Carotid Stenosis (Carotid Artery Stenosis) 03/2020 - 06/2018
3	Infections 03/2019 - 01/2012
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2012 - 01/2004
2	Ischemic Stroke 01/2021 - 09/2019
2	Neoplasms (Cancer) 01/2019 - 12/2007
2	Stroke (Strokes) 01/2019 - 09/2014
2	Experimental Arthritis 05/2015 - 01/2009
2	Inflammation (Inflammations) 05/2015 - 01/2012
2	Castleman Disease (Castleman's Disease) 03/2015 - 02/2014
2	Polymyositis 01/2012 - 07/2011
2	Seasonal Allergic Rhinitis (Hay Fever) 09/2009 - 01/2009
2	Asthma (Bronchial Asthma) 06/2007 - 04/2006
2	Bone Diseases (Bone Disease) 01/2005 - 01/2002
1	Carcinogenesis 04/2022
1	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2022
1	COVID-19 01/2022
1	Intracranial Embolism 07/2021
1	Patent Foramen Ovale 07/2021
1	Aneurysm (Aneurysms) 07/2021
1	Hemorrhagic Stroke 10/2020
1	Cytopenia 01/2020
1	Primary Myelofibrosis (Myelosclerosis) 01/2020
1	Intestinal Perforation 03/2019
1	Thrombocytopenia (Thrombopenia) 03/2019
1	Dyslipidemias (Dyslipidemia) 03/2019
1	Neutropenia 03/2019
1	Prolactinoma (Prolactinomas) 01/2019
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2019
1	Rheumatic Fever (Acute Articular Rheumatism) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Myocardial Infarction 01/2019
1	Spinal Dysraphism (Spina Bifida) 01/2018
1	Scoliosis 01/2018
1	Hypoxia (Hypoxemia) 06/2017
1	Brain Neoplasms (Brain Tumor) 06/2017
1	Xerostomia 03/2017
1	Taste Disorders (Taste Disorder) 03/2017

Drug/Important Bio-Agent (IBA)

23	tocilizumab (atlizumab)FDA Link 09/2019 - 12/2009
9	Interleukin-6 (Interleukin 6)IBA 03/2019 - 10/2007
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2003
5	Monoclonal AntibodiesIBA 01/2019 - 01/2012
4	AntibodiesIBA 01/2022 - 03/2014
4	C-Reactive ProteinIBA 03/2019 - 05/2003
4	Tumor Necrosis Factor InhibitorsIBA 01/2014 - 11/2010
3	Peptides (Polypeptides)IBA 01/2021 - 12/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2017 - 03/2002
3	FlavonoidsIBA 09/2009 - 06/2007
3	Interleukin-18 (Interleukin 18)IBA 04/2006 - 05/2003
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2003 - 03/2002
2	AntigensIBA 03/2020 - 04/2010
2	Glycophorins (Glycophorin C)IBA 03/2020 - 06/2018
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 08/2011
2	EnzymesIBA 03/2019 - 11/2010
2	LigandsIBA 01/2019 - 12/2007
2	Leucine (L-Leucine)FDA Link 05/2015 - 04/2010
2	Glycoproteins (Glycoprotein)IBA 05/2015 - 04/2010
2	Methotrexate (Mexate)FDA LinkGeneric 01/2015 - 11/2010
2	Biological ProductsIBA 03/2014 - 01/2012
2	Antirheumatic Agents (DMARD)IBA 03/2014 - 11/2010
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2012 - 01/2012
2	QuercetinIBA 09/2009 - 01/2009
2	isoquercitrinIBA 09/2009 - 01/2009
2	GlycosidesIBA 09/2009 - 01/2009
2	Diphosphonates (Bisphosphonates)IBA 01/2005 - 01/2002
1	antiglomerular basement membrane antibodyIBA 04/2022
1	NucleotidesIBA 01/2021
1	CalreticulinIBA 10/2020
1	Coloring Agents (Dyes)IBA 03/2020
1	ProlactinIBA 01/2019
1	Cabergoline FDA LinkGeneric 01/2019
1	General AnestheticsIBA 01/2019
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	PCSK9 InhibitorsIBA 01/2019
1	Interleukin-8 (Interleukin 8)IBA 01/2019
1	alirocumabIBA 01/2019
1	Proprotein Convertase 9IBA 01/2019
1	LipidsIBA 01/2019
1	LDL CholesterolIBA 01/2019
1	Certolizumab Pegol FDA Link 01/2018
1	ZincIBA 03/2017
1	CD100 antigenIBA 06/2015
1	CytokinesIBA 06/2015

Therapy/Procedure

14	Therapeutics 04/2022 - 01/2005
3	Carotid Endarterectomy 03/2020 - 06/2017
3	Drug Therapy (Chemotherapy) 06/2017 - 01/2002
2	Thrombectomy 01/2021 - 09/2019
1	Orthopedic Procedures 07/2021
1	Stents 01/2021
1	Catheters 11/2020
1	Cardiopulmonary Resuscitation (CPR) 01/2018
1	Radiotherapy 03/2017
1	Ligation 01/2017